BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
2/24/2023 1:35:50 PM | Browse: 171 | Download: 274
 |
Received |
|
2022-12-09 15:45 |
|
Peer-Review Started |
|
2022-12-09 15:48 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2022-12-24 22:37 |
|
Revised |
|
2022-12-30 19:27 |
|
Second Decision |
|
2023-01-18 03:19 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Company Editor-in-Chief |
|
2023-01-18 23:27 |
|
Articles in Press |
|
2023-01-18 23:27 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2023-01-19 08:11 |
|
Publish the Manuscript Online |
|
2023-02-24 13:35 |
| ISSN |
1948-5182 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Letter to the Editor |
| Article Title |
Glecaprevir/pibrentasvir + sofosbuvir for post-liver transplant recurrent hepatitis C virus treatment
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Rishi Arora, Michelle T Martin, Justin Boike and Sonalie Patel |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Sonalie Patel, PharmD, Pharmacist, Division of Hepatology , Northwestern Medicine, 676 N St. Clair 560, Chicago, IL 60611, United States. sonalie.patel@nm.org |
| Key Words |
Hepatitis C virus; Direct-acting antivirals; Liver transplantation; Glecaprevir/pibrentasvir; Sofosbuvir; Ribavirin |
| Core Tip |
In the post-liver transplant population, current national guidance only recommends sofosbuvir/velpatasvir/voxilaprevir, with or without ribavirin, for recurrent hepatitis C virus treatment in direct-acting antiviral-experienced patients. We describe an alternative regimen of glecaprevir/pibrentasvir in combination with sofosbuvir that resulted in sustained virologic response without treatment-related adverse events. |
| Publish Date |
2023-02-24 13:35 |
| Citation |
Arora R, Martin MT, Boike J, Patel S. Glecaprevir/pibrentasvir + sofosbuvir for post-liver transplant recurrent hepatitis C virus treatment. World J Hepatol 2023; 15(2): 318-320 |
| URL |
https://www.wjgnet.com/1948-5182/full/v15/i2/318.htm |
| DOI |
https://dx.doi.org/10.4254/wjh.v15.i2.318 |
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
